![conference banner](/images/conference-banner.jpeg)
Abstract
Hepatocellular Carcinoma (HCC) is one of the most common malignancies, and its incidence and mortality are increasing worldwide. Cancer immunotherapy has revolutionized cancer treatment in recent years. In particular, immune checkpoint inhibitors (ICIs), as new therapeutic tools, have demonstrated encouraging antitumor activity and manageable tolerability in HCC. Immune checkpoint blockade with antibodies targeting Programmed cell Death-1 (PD-1), Programmed cell Death Ligand-1 (PD-L1), and cytotoxic T lymphocyte-associated protein-4 (CTLA- 4) enhances tumor immunity by restoring exhausted T cells. Although the efficacy of combinational treatment strategies using ICIs combined with other ICIs, molecularly targeted agents, systemic therapy, or locoregional therapy has been well documented in numerous preclinical and clinical studies in several types of cancer, most HCC patients do not benefit from ICI treatment. This review highlights recent developments and potential opportunities related to ICIs and their combination in the management of HCC. The present article also reviews recent patents related to ICIs.
Keywords: Hepatocellular carcinoma, immunotherapy, immune checkpoint inhibitors, combination treatment, programmed cell death-1 (PD-1), cytotoxic T lymphocyte-Associated protein-4 (CTLA-4).
Recent Patents on Anti-Cancer Drug Discovery
Title:Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
Volume: 16 Issue: 2
Author(s): Jing Bai, Ping Liang, Qian Li, Rui Feng*Jiang Liu*
Affiliation:
- Department of Pharmacy, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei Province,China
- Department of Pharmacy, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei Province,China
Keywords: Hepatocellular carcinoma, immunotherapy, immune checkpoint inhibitors, combination treatment, programmed cell death-1 (PD-1), cytotoxic T lymphocyte-Associated protein-4 (CTLA-4).
Abstract: Hepatocellular Carcinoma (HCC) is one of the most common malignancies, and its incidence and mortality are increasing worldwide. Cancer immunotherapy has revolutionized cancer treatment in recent years. In particular, immune checkpoint inhibitors (ICIs), as new therapeutic tools, have demonstrated encouraging antitumor activity and manageable tolerability in HCC. Immune checkpoint blockade with antibodies targeting Programmed cell Death-1 (PD-1), Programmed cell Death Ligand-1 (PD-L1), and cytotoxic T lymphocyte-associated protein-4 (CTLA- 4) enhances tumor immunity by restoring exhausted T cells. Although the efficacy of combinational treatment strategies using ICIs combined with other ICIs, molecularly targeted agents, systemic therapy, or locoregional therapy has been well documented in numerous preclinical and clinical studies in several types of cancer, most HCC patients do not benefit from ICI treatment. This review highlights recent developments and potential opportunities related to ICIs and their combination in the management of HCC. The present article also reviews recent patents related to ICIs.
Export Options
About this article
Cite this article as:
Bai Jing , Liang Ping , Li Qian , Feng Rui *, Liu Jiang *, Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma, Recent Patents on Anti-Cancer Drug Discovery 2021; 16 (2) . https://dx.doi.org/10.2174/1574892816666210212145107
DOI https://dx.doi.org/10.2174/1574892816666210212145107 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Adding to the Mix: Fibroblast Growth Factor and Platelet-Derived Growth Factor Receptor Pathways as Targets in Non – small Cell Lung Cancer
Current Cancer Drug Targets Machine Learning in Magnetic Resonance Images of Glioblastoma: A Review
Current Medical Imaging Design, Preparation and Characterization of Modular Squalene-based Nanosystems for Controlled Drug Release
Current Topics in Medicinal Chemistry Competition Between Tumor and Mononuclear Phagocyte System Causing the Low Tumor Distribution of Nanoparticles and Strategies to Improve Tumor Accumulation
Current Drug Delivery Cardiotoxicity of Molecularly Targeted Agents
Current Cardiology Reviews 68Ga/64Cu PSMA Bio-Distribution in Prostate Cancer Patients: Potential Pitfalls for Different Tracers
Current Radiopharmaceuticals Anesthetic Cardioprotection in Clinical Practice From Proof-of-Concept to Clinical Applications
Current Pharmaceutical Design Monoclonal Antobodies: Application in Radiopharmacy
Current Radiopharmaceuticals Food Color Additives in Hazardous Consequences of Human Health: An Overview
Current Topics in Medicinal Chemistry Monocarboxylate Transporter 1 in Brain Diseases and Cancers
Current Drug Metabolism Lymphatic Endothelial Cells, Inflammatory Lymphangiogenesis, and Prospective Players
Current Medicinal Chemistry Ras-MAPK Pathway as a Therapeutic Target in Cancer - Emphasis on Bladder Cancer
Recent Patents on Anti-Cancer Drug Discovery The Role of Hypoxia in Endometrial Cancer
Current Pharmaceutical Biotechnology Beetroot Bioactive and its Associated Health Benefits: Considerations for Utilization of Beetroot in Value-added Products
Recent Advances in Food, Nutrition & Agriculture The Role of Leukotrienes Inhibitors in the Management of Chronic Inflammatory Diseases
Recent Patents on Inflammation & Allergy Drug Discovery PRDM14: A Potential Target for Cancer Therapy
Current Cancer Drug Targets Cancer Pharmacogenomics: Germline DNA, Tumor DNA, or Both?
Current Pharmacogenomics Biological and Clinical Significance of Polymorphisms in NAD(P)H: Quinone Oxidoreductase 1 (NQO1)
Current Pharmacogenomics Genetic and Molecular Approaches to the Immunopathogenesis of Multiple Sclerosis: An Update
Current Molecular Medicine Multiple Target-Specific Molecular Agents for Detection and Image Analysis of Breast Cancer Characteristics in Mice
Current Molecular Medicine